Drug Trial News

RSS

New MS treatment found safe, tolerable in phase I clinical trials

A new treatment under investigation for multiple sclerosis (MS) is safe and tolerable in phase I clinical trials, according to a study published August 27, 2014, in Neurology Neuroimmunology & Neuroinflammation, a new online-only, freely accessible, specialty medical journal.

28 Aug 2014

Experimental drug shows promise as viable treatment for anemia of inflammation

An experimental drug designed to help regulate the blood's iron supply shows promise as a viable first treatment for anemia of inflammation, according to results from the first human study of the treatment published online today in Blood, the Journal of the American Society of Hematology.

28 Aug 2014

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Asterias Biotherapeutics Inc. has received clearance from the U.S. Food and Drug Administration to initiate a Phase 1/2a clinical trial of its product, AST-OPC1, in patients with complete cervical spinal cord injury.

27 Aug 2014

Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Ruthigen Inc., a biopharmaceutical company focused on improving patient outcomes and reducing healthcare costs in invasive procedures, has announced that its lead drug candidate, RUT58-60, has received a recommendation from the Data Monitoring Committee to begin enrolling patients in the Company's planned Phase 1/2 clinical trial.

26 Aug 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

Actavis files ANDA for generic version of Neupro

Actavis plc today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Rotigotine Extended-release Transdermal Film, 1 mg/24 hr, 2mg/24 hr, 3 mg/24hr, 4 mg/24 hr, 6mg/24hr, and 8 mg/24 hr.

25 Aug 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

22 Aug 2014

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Nektar Therapeutics reports Baxter International Inc. today announced positive results from its Phase 3 pivotal clinical trial of BAX 855, an investigational, extended half-life recombinant factor VIII (rFVIII) treatment for hemophilia A based on ADVATE [Antihemophilic Factor (Recombinant)], which met its primary endpoint in reducing annualized bleed rates (ABR) in the prophylaxis arm compared to the on-demand arm.

From Baxter International Inc. 22 Aug 2014

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive results from a randomized, double-blind Phase 2a study of collagenase clostridium histolyticum (or CCH) for the treatment of edematous fibrosclerotic panniculopathy (EFP), commonly known as cellulite.

21 Aug 2014

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Trovagene, Inc., a developer of cell-free molecular diagnostics, announced today that results from two clinical studies will be presented at the 29th International Papillomavirus conference for the Company's urine-based diagnostic test for the detection of high risk strains of Human Papillomavirus.

20 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME.

20 Aug 2014

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

Actavis plc today confirmed positive topline results from RECLAIM-1 and -2, pivotal Phase III studies evaluating the potential for the investigational antibiotic, ceftazidime-avibactam as a treatment for adult hospitalized patients with complicated intra-abdominal infections.

19 Aug 2014

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo Therapeutics Inc., today reported results of its Oral Amphotericin B (Oral Amp B) drug candidate targeting latent HIV reservoirs.

19 Aug 2014

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Amgen (NASDAQ: AMGN) today announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its primary and all secondary endpoints.

19 Aug 2014

$Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment$

Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment

It's time to question the common belief that patients receiving intensive blood pressure treatment are prone to falling and breaking bones. A comprehensive study in people ages 40 to 79 with diabetes, led by Karen Margolis, MD, of HealthPartners Institute for Education and Research in the US, found no evidence supporting this belief.

19 Aug 2014

Neo40 nitric oxide supplement helps promote normal blood pressure

Nitric oxide supplementation using a Neo40 lozenge significantly helps promote normal blood pressure, as indicated by a 30-day, blinded, placebo-controlled clinical study, conducted at the California Medical Institute by renowned cardiology researcher Dr. Ernst Schwarz.

18 Aug 2014

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

A modified version of the Clostridium novyi (C. novyi-NT) bacterium can produce a strong and precisely targeted anti-tumor response in rats, dogs and now humans, according to a new report from Johns Hopkins Kimmel Cancer Center researchers.

14 Aug 2014

Clinical trial tests COXEN model in bladder cancer to find promising treatment

Imagine being able to match a cancer's genes to the best treatment. That's the promise of COXEN (CO eXpression ExtrapolatioN) - a computer program that looks at a panel of cancer genes in a patient's tumor to predict whether it will respond to chemotherapy.

14 Aug 2014

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy.

13 Aug 2014

Drug Trial News

New MS treatment found safe, tolerable in phase I clinical trials

Experimental drug shows promise as viable treatment for anemia of inflammation

Asterias receives clearance from FDA to initiate Phase 1/2a clinical trial of AST-OPC1

Ruthigen gets DMC recommendation to begin RUT58-60 Phase 1/2 clinical trial

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Actavis files ANDA for generic version of Neupro

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Baxter reports positive results from BAX 855 Phase 3 trial for hemophilia A

Auxilium Pharmaceuticals' CCH drug effective against cellulite in Phase 2a study

Trovagene announces results from clinical studies on urine-based diagnostic test for detection of HPV

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

Actavis reports positive results from ceftazidime-avibactam Phase III studies in cIAI patients

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Amgen’s AMG 416 Phase 3 placebo-controlled study meets primary and secondary endpoints

Study on patients with type 2 diabetes examines fracture risk with antihypertensive treatment

Neo40 nitric oxide supplement helps promote normal blood pressure

Modified C. novyi-NT bacterium produces precisely targeted anti-tumor response

Clinical trial tests COXEN model in bladder cancer to find promising treatment

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News